Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

Research in genetics and biotechnology has advanced by leaps and bounds in recent years, offering new hope for the treatment ...

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug (IND) application to begin ...

The articles in this special issue highlight the diversity and complexity of research into reproductive health, including the need for a better understanding of the fundamental biology of reproduction ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

Authenticated data presented in the Life science tools market report is based on findings of extensive primary and secondary research.